FIELD: medicine; pharmaceuticals.
SUBSTANCE: treatment of estrogen-driven cancer. The following is disclosed: the use of a SERD connection, which is
or a pharmaceutically acceptable salt thereof, in combination with a CDK4/6 inhibitor compound that is
or a pharmaceutically acceptable salt thereof; for the treatment of estrogen-dependent breast cancer in a person in need thereof, as well as a pharmaceutical composition containing such a combination for the treatment of estrogen-driven breast cancer.
EFFECT: use of the invention makes it possible to effectively treat estrogen-dependent breast cancer.
13 cl, 15 dwg, 11 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZOTHIOPHENE SELECTIVE ESTROGEN RECEPTOR BLOCKERS | 2016 |
|
RU2747802C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE ANTI-ESTROGENIC DRUGS | 2016 |
|
RU2745742C1 |
| PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | 2013 |
|
RU2659936C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| METHOD FOR TREATMENT OF ANDROGEN RECEPTOR (AR)-POSITIVE FORMS OF BREAST CANCER USING SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) | 2013 |
|
RU2648959C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
